Q2 2022 Elanco Animal Health Inc Earnings Call
Six of todays slides and in the earnings press release after our prepared remarks, we'll be happy to take your questions.
I'll now turn the call over to Jeff.
Thanks, Katie and good morning, everyone.
<unk> continues to execute our innovation productivity and portfolio strategy, while delivering in the second quarter in particular, our companywide productivity agenda continued to deliver and we are pleased with the progress on our innovation pipeline.
While we now expect some challenges mostly macro environmental challenges to our topline performance over the remainder of the year, we expect to return to constant currency sales growth in the fourth quarter of this year, our companywide productivity efforts continue to drive margin expansion, our pipeline progress as laying groundwork for fuel.
Your growth and our commercial teams continue to help customers around the globe treat animals with our diversified global portfolio.
In the second quarter.
Out of the <unk> team for increasing adjusted EBITDA, 3% and adjusted EPS, 29%. Despite the revenue decline of 4% in constant currency, which was in line with our May guidance <unk>.
<unk> focus over the last year on productivity efforts to reduce costs by streamlining our sales and marketing organizations prioritizing resources in R&D and across our manufacturing footprint allowed us to exceed our top end of our second quarter guidance range with adjusted EPS of <unk> 36, and adjusted EBITDA.
$300 million. Additionally, we delivered strong operating cash flow in the quarter and reduced our net leverage ratio to five three times down from five six times at the end of the first quarter.
Today, we are updating our revenue outlook for 2022 to account for economic environmental and company specific factors that accelerated and intensified in the quarter.
We are taking a measured and balanced approach to this environment and this forecast.
Given these dynamics we are also adjusting the timeline by which we expect to achieve our longer term margin targets laid out at our December 2020, Investor day. Despite today's reduction in our sales expectations for 2022, we expect to expand both gross margin and EBITDA margin this year and.
Back to that to continue in 2023 and 2024, we remain committed to 60% gross margin and 31% adjusted EBITDA margin and we will provide an update on timing in 2023.
Moving to slide four let's start with our second quarter sales results. We reported revenue of 1.1 dollars 77 billion, a decline of 8% and reported revenue of 4% in constant currency.
We delivered 3% constant currency growth in farm animal driven by 6% growth in the U S led by Zoa shield in poultry and moments in cattle.
Our international farm animal business grew 1% in constant currency has strength in ruminant, including sheep was partially offset by softness in our swine business in China and to a lesser extent Europe .
Although in Notionally smaller business, we continued to see strong performance in Aqua with 5% constant currency growth. Despite the $10 million of phasing into the first quarter, we discussed in May which drove Q1 growth of 96%.
Pet health declined in Q2 by 7% in constant currency, our U S business declined 11% driven by competitive pressure on our vet based parasiticide, including <unk> and interceptor, plus and declines across our retail portfolio.
We do not believe this level of sales decline is indicative of the underlying quality of our U S. Pet health business has supply and other discrete issues impacted the business in the quarter. We are confident it will improve as we move forward through the back half of the year.
International Pet health was flat in the quarter and China, Our pet health business was also flat in the quarter driven by the impact of two months of Covid. Lockdowns. These results are in contrast to the significant double digit growth. The team delivered in 2021 and the first quarter of 2022.
Additionally, I'd like to address our second quarter price growth of 1%.
<unk> growth in pet health was below our initial expectations, but reflects an intentional shift in our U S. Retail business, we invested further in promotional investments or trade funds with our retail partners to drive demand that increased our gross to net spend thus reducing net sales from price.
This trade fund investment was a shift in spend from marketing operating expense and created a net positive contribution to EBITDA.
Price growth and farm animal was driven by our international business and U S farm animal price was lower than our expectations driven by competitive dynamics and the pricing actions in the bovine respiratory disease market impacting and correct Seth.
Mid year price increases have been taken across both pet health and farm animal portfolios and we expect to see accelerating contribution in the second half with full year price growth more in line with our historical 2% levels moved.
Moving to slide five we are reducing our full year sales guidance from an expected constant currency growth of 2% to 3% to now flat to minus 2% compared to our May guidance. This is a $220 million reduction at the midpoint of the range to reflect our current assumptions that can be grouped into three areas.
First approximately $65 million from the unfavorable impact of foreign exchange rates.
Now expect a total headwind of $205 million from dollar strength compared to $140 million, we expected in early may.
Secondly, a $100 million to $120 million from macro environmental factors, including the pace of recovery from China's Covid Lockdown disruptions in the global supply chain and pressure from the expected economic slowdown around the world.
And finally, a net $40 million to $50 million or one percentage point drag on growth from performance headwinds relating primarily to pricing realization innovation ramp in U S Pet health care set asides.
Regarding $100 million to $120 million reduction from macro environmental factors, let's start with China, which is $60 million to $65 million of that reduction.
We had been expecting our China business to grow by 22% at constant currency and to provide about a percentage point of growth from totally langkow. This year as it did in 2021 with this revenue change we now expect China to decline by approximately 1% this year in constant currency.
For pet health as the major population centers in China were under strict Lockdowns. Our assumption in May was for a rebound in pent up demand starting in June that would result in a V shaped recovery similar to what we saw in the U S. In 2020, while we saw some improvement through June and into July .
It does not appear to second half bounce back will materialize as expected.
And we now see a more tempered pace of growth in the second half than we did in may.
In the first quarter of the year <unk> strong team in China grew market share six percentage points in the parasiticide market through its commercial capabilities and strong portfolio that has just been enhanced with the approval of <unk>, while we don't expect to recapture our lost sales from Q2 as we projected in May we still <unk>.
Spect, our China pet health business to grow double digits in the second half of the year.
Moving to farm animal in China, swine prices are improving but are expected to remain volatile the large industrial swine producers have a higher cost base coming out of the African swine fever impacting their ability to invest in our products as current prices remain below their breakeven levels.
Additionally, the lower protein demand overall from the Covid Lockdowns and competition from cheaper pork is also impacting our poultry business, where prices have been depressed and tracking below our expectations for the year.
Despite the current environmental headwinds in China.
We believe we are very well positioned in both pet health and farm animal to take advantage of the recoveries as they occur and believe China will be a growth driver for <unk> in 2023 10 years to come.
Next moving to the supply chain disruption, which represents 30% to $35 million of our sales reduction from macro environmental factors, while the paper and packaging challenges from the first half are largely behind us freight and logistics remains dynamic in a number of our suppliers and Cmos are experiencing ongoing input sort.
<unk> challenges and labor shortages, we expect these issues to negatively impact our ability to meet demand for a number of smaller products, primarily in our international farm animal business. We continue to seek alternative sources of raw materials and other inputs to drive more reliable supply performance in 2023.
Lastly, we expect the reality of the economic slowdowns across the world will create a $10 million to $20 million downside and our global business.
Finally, we are reducing our revenue guidance by approximately $40 million to $50 million to reflect our lowered expectations for innovation sales ramp price growth and performance of our U S Pet health parasiticide business, which will more than offset better than expected performance in poultry Aqua and contract manufacturing.
While I covered price earlier for innovation sales, we're lowering our expectations by $20 million to $30 million to a $100 million to $130 million for the full year as a result of our updated expectations for Xperia and Cressa and <unk> plus.
For Xperia, we are very pleased with the customer experience feedback. We're receiving is the number of customers using the product and the number of had unexpired continues to increase.
However, the feed yard adoption curve as behind our expectations for May and.
Important to point out twice the number of cattle started on experience in the second quarter than in Q1 and more cattle started in July than we saw in all of Q2.
We continue to expect experience to become a blockbuster and industry feedback in recent months has only strengthened this belief.
Given the current strong ramp in cattle on the product, we expect experience would be a major growth driver and accretive to gross margin in 2023.
Finally, as we evaluated the results of this year's flea and tick season, we think the competitive pressure across the portfolio will likely be closer to 75 or $80 million rather than our previous 60 million assumptions, we see the majority of the additional pressure on dog products as growth in <unk> for cats.
<unk> is strong.
While these headwinds and innovation pricing and parasiticide create a net negative on our sales expectations the strength in our Aqua and poultry business and higher contract manufacturing sales are expected to provide a positive offset our commercial teams continue to deliver in areas, where our portfolio has competitive strength lay.
Later, Todd will take you through the adjusted EBITDA and adjusted EPS from the changes in the topline guidance now I would like to transition to provide more information on the resto and our progress on innovation.
In the second quarter Sorretto declined approximately 6% constant currency and was below our expectations. The decline was driven by a softer season in the U S and Europe , lower retail inventory levels and competitive dynamics for.
For the first half the brand grew approximately 2% in constant currency with total sales of $273 million.
In June I appeared before the house Subcommittee on economic and consumer policy in support of Sorrento defending its strong safety profile and the importance of protecting dogs and cats against disease carrying fleas and ticks during my testimony I reiterated our commitment to work with EPA supporting science based evaluations.
The product we continue to provide additional data and analysis that supports <unk> strong safety profile.
<unk> has been challenged in the U S. The last two years. It has generally performed in line with our expectations across the rest of the world.
Aligned with the historical data in July our U S. Consumer research shows repurchase intent of 95% for Sorrento, demonstrating high customer loyalty, we see <unk> as a resilient affordable brand that meets unique market needs and are very focused on driving brand growth in years to come.
Transitioning to slide six the most important driver of future growth free Langkow is our innovation portfolio. We continue to expect the products launched in 2021 and beyond to contribute $600 million to $700 million of revenue by 2025.
The leadership of Dr. <unk> and the disciplined execution of our experienced team over the last nine months has increased our confidence in the next era of innovation coming from new platforms and spaces, including monoclonal antibodies sustainable protein and pet therapeutics as well as pet parasiticide since.
Our last earnings call in May we continued to advance our late stage pipeline delivering approvals and increasing probabilities.
Within the next two to four months, we intend to make regulatory submissions for a broad spectrum parasiticide product and one of our late stage dermatology products. The submissions will start the regulatory review process, which is iterative and rolling in nature, where the approval timing dependent on the regulatory body involved with FDA, we typically expect.
A 12 months to 18 months review cycle from initial submission to approval, while the USDA and the European authorities are often shorter.
For our parasiticide product, we believe we have crossed the so-called heartworm threshold a challenge we faced several years ago with <unk> plus in the U S development program. We believe our late stage assets are differentiated from the current market offerings and we'll continue to update you on any material developments.
We remain on track for seven approvals in 2022 with six of the seven expected approvals in major markets now received these.
These portfolio enhancing products are primarily in pet health, including <unk>, and China, <unk>, plus in Canada and advantage XD for cats in the U S. Additionally, our parvovirus treatment for dogs continues to advance with USDA approval expected late this year or early 2023.
Finally, we continue to build a leading feline portfolio that we believe will improve the standard of cat care in.
In July we launched <unk>, a long acting post operative transdermal pain product, which is gaining traction in vet clinics. It's innovative delivery mechanism makes post operative care easier on cats and their owners delivering value to veterinarians as evidenced by 5000 clinic placements in the first month.
We're also pleased to announce today that we've licensed a revolutionary first in class product for feline diabetes care the product introduces a new mechanism of action for veterinarians with a needle free easy to give daily oral medication to treat this chronic condition.
The product is under FDA regulatory review and expected to be approved within the next 12 months.
In addition to these near term innovations such as canine influenza and parvovirus demonstrate <unk> commitment to bringing novel and differentiated innovations and will serve as important relationship builders with veterinarians are ahead of our expected broad spectrum parasiticide and multiple dermatology products coming.
To the market.
We plan to have Alan join our third quarter earnings call in November to provide further updates on innovation efforts and portfolio progress.
Before I turn the call over to Todd I would like to thank the Langkow team for all of their productivity efforts over the last few years, our introduction of an Eva like performance metric into our short term compensation, which we call. The Langkow cash earnings is driving a company wide ownership mindset and intensifying our focus on <unk>.
<unk> capital optimization I believe this mindset and ownership culture will drive value for all stakeholders over the long term now ill hand, it over to Todd.
Thank you, Jeff and good morning, everyone. Today I'll focus my comments on our second quarter adjusted measures. So please refer to today's earnings press release for a detailed description of the year over year changes in our reported results.
Starting on slide eight we delivered 117 $7 billion in revenue of 8% decline were 4% decline in constant currency with price growing 1%.
Foreign exchange rates represented a headwind of $56 million in the quarter or 4% slightly above our expectations.
Slide nine breaks down our revenue performance both species and slide 10 provides revenue by region in the quarter.
For pet health, we've declined 7% in constant currency for the quarter with our international business flat in constant currency and our U S business declining 11%.
Vantage family of products contributed $137 million, representing a 7% decline on a reported basis or a 3% decline in constant currency driven by supply challenges and softness in Europe , <unk> contributed $113 million, representing a 12% decline on a reported basis or a 6%.
Decline in constant currency with softness in the U S and central Europe , where the Russian invasion of Ukraine negatively impacted our business, partially offset by growth in western Europe .
More broadly <unk> grew double digits globally vaccines remained steady growing dispensing within a market growing mid single digits and on a year to date basis. Gallup ranked grew double digits in the U S. While weather and competition in Europe .
Our farm animal business grew 3% at constant currency, including 2% from price, primarily driven by our international business.
<unk> growth was primarily driven by the international ruminant business, notably sheet products. Additionally, the quarter benefited from a shift in timing for generic defense programs for events and ahead of our midyear price increase shifting sales expected in the third quarter of 2022 into the second growth was offset by pressure to economics for <unk>.
Wine and poultry producers in China, and a decline for swine in Europe .
Slide 11 further summarizes our financial performance for the second quarter. Despite.
Despite the decrease in reported sales gross margin improved 190 basis points to 58, 9%, primarily driven by continued improvements in manufacturing productivity, a weaker euro and price, partially offset by inflation in input costs and.
And conversion costs, and an unfavorable mix from lower sales and pet health.
Operating expenses for the quarter were $425 million, a reduction of 11% year over year.
Pact of FX on expenses was approximately $14 million favorable in the second quarter or a 3% benefit year over year. This.
This improvement highlights our disciplined execution and demonstrates our ability to sustain synergies and cost savings from our restructuring actions, while more than offsetting inflation and continuing to invest in key strategic priorities.
Our R&D spend was in line with expectations as we concentrated investments going into this year and prioritize our pet health blockbuster development pipeline.
Interest expense was $50 million in the quarter or year over year decline of 17% driven by the repayment of our 2021 senior notes last August .
The non-GAAP effective tax rate was 18% for the quarter, which provided a benefit of <unk> <unk> per share above our expectations. This lower Q2 rate was driven by the jurisdictional mix of Alanco profits and discrete items, we still expect our full year tax rate to be approximately 25% to 26%. Despite the lower Q2 rate.
Adjusted net income was $177 million and adjusted EPS was <unk> 36.
For the quarter, reflecting growth of 31% and 29% respectively.
Adjusted EBITDA was $300 million in the quarter or about $40 million better than the midpoint of our guidance.
We expect to file our 10-Q in the coming days, but let's move to the balance sheet and cash flow metrics on slide 12.
We ended the quarter with $5 $63 billion in net debt a reduction compared to the first quarter of 2022 of $240 million.
Our net debt to adjusted EBITDA ratio at the end of Q2 was five three times, which improved from five six times at the end of Q1, we expect the net debt to adjusted EBITDA ratio to continue to improve in the second half I would expect the first year at approximately five times.
In the second quarter, our operating cash flow was $312 million, reflecting the lower reported net loss in the quarter year over year and a one time benefit of net $124 million from a cash interest rate swap settlement.
So that provides a cash benefit in the second quarter that will create a headwind in operating cash flow over the next four years as this cash acceleration reverses excluding the swap benefit operating cash would have increased 21% over the second quarter of 2021.
Next let's transition to our updated outlook for 2022 on slide 14.
For the full year, we now expect revenue to be between $4 46, five and $4 $5 $5 billion or flat to down 2% year over year in constant currency, reflecting the details Jeff has already provided on sales.
The bridge from our May guidance can be found on slide 15.
While in the second quarter, our productivity initiatives allowed us to deliver higher adjusted EBITDA and adjusted EPS that our guidance projected despite sales only at the midpoint of guidance, we do not expect that to be the case in the second half of this year, we continue to see higher inflation negatively impacting our manufacturing and supply chain networks.
Wage inflation is now negatively impacting our business as well for the full year, we expect inflation to impact our manufacturing costs by $140 million or $20 million more than we projected in may.
As you can see in the bridge on Slide 16, we now expect adjusted EBITDA between 1.06 billion and $1 $1 billion for 2022, which is a $65 million reduction from the midpoint of the range provided in may the.
The stronger U S dollar drives approximately $20 million of the change while the other $45 million is driven by the approximate $55 million of over achievement and adjusted EBITDA in the first two quarters of the year more than offset by the gross profit drop through from the sales reduction in the second half and incremental inflation.
We now expect adjusted diluted EPS of $1 six to $1 13 for 2022, which is a reduction of 8% versus the midpoint of the range provided in may.
The stronger U S. Dollar is driving approximately <unk> of the reduction.
The other five is driven by the sales reduction partially offset by a smaller amount of increased productivity and the operational over achievement in the second quarter.
Finally, we are introducing guidance for the third quarter of 2022 on slide 17, we expect revenue of 1.01 billion to 1.06 billion adjusted EBITDA between $175 million and $215 million and adjusted EPS between 12 and 18 sets.
The constant currency projected revenue decline of 3% at the midpoint is driven by expected declines in ruminants, <unk> swine and contract manufacturing, partially offset by expected growth in poultry and Aqua, we expect pet health to be generally flat.
While we aren't guiding to the fourth quarter explicitly growth at the midpoint of the implied range is 2%.
Moving to slide 18 adjust mentioned earlier, we're extending the timeline for the achievement of our 60% gross margin and 31% adjusted EBITDA margin from 2023 and 2024, respectively. This change is driven primarily by the degradation in the global macro environment since we establish these targets.
In December of 2020, with respect to inflation supply chain disruptions and a longer recovery in China from Covid Lockdowns as well as the unfavorable impact of sales mix on gross margin. While these factors have accelerated and intensified since may we have not changed the timeline before today because our pro.
Activity initiatives have continued to deliver ahead of our expectations.
Although it's hard to adjust for just one factor when you reduce our cost of goods sold in 2022 by approximately $100 million.
To reflect the incremental inflation compared to what we had expected during the December 2020, Investor Day, We would project a 60% gross margin this year.
That incremental $100 million of gross profit would have also increased our adjusted EBITDA margin by over 200 basis points, which would have had is tracking to our 31% target for 2024.
Our reality is different and the things. We have described are causing us to change the timing of achieving these targets, but not changing our expectation that we will continue to expand our margins in 2023 and 2024.
As we noted in February our value capture expectations or ahead of schedule and the integration of the bear ERP system and business processes. Those on track, we still expect this integration to deliver $50 million to $60 million of adjusted EBITDA savings in 2024.
Moreover, as China recovers xperia ramps supply chain improve and we continue to capture price all of our productivity measures over the last few years, we will drive continued margin expansion.
We plan to update the timeline for achieving our 60% and 31% targets in 2023.
With that I'll hand, it back to Jeff for closing comments. Thanks, Todd any land go we are building a long term sustainable company.
Over the past two years, we've created a stronger more durable and diverse company our efforts to streamline and drive efficiency are delivering significant productivity, improving profitability and cash generation, allowing us to pay down debt and continue investing in the business. The team has executed.
Beyond our expectations and are progressing on our next significant initiative, which is integrating the Bayer animal health business into our systems and processes. While we are in a challenged environment. This quarter demonstrates our strategy is working and we are better positioned to weather. These challenges.
As a result of our company transformation fundamentally animal health remains an attractive industry that has underlying macro growth drivers in both pets and protein is resilient to challenges and it rewards innovation.
We are accelerating progress on our innovation with opportunities to bring best in class solutions to address unmet needs and revolutionize care.
As the pipeline delivers we expect to leverage our established cost base to fuel more margin expansion bigger.
Beginning with our pet health blockbusters submissions in the next two to four months. This opens the door to our next era of innovation and growth that will deliver increased value to customers and shareholders with that I'll turn it over to Katie to moderate the Q&A. Thanks, Jeff.
We'd like to take questions from as many callers as possible. So we ask that you limit yourself to one question and one follow up.
Operator, please provide the instructions for the Q&A session and then we'll take the first caller.
At this time, if you'd like to ask a question simply press star followed by the number one on your telephone keypad again that is star one our first question will come from the line of Erin Wright with Morgan Stanley . Please go ahead.
Great. Thanks, So first on 2022 guidance.
Can you speak to some of the company specific factors you called out the first on incremental price headwind embedded in your guidance is that tied to the dynamics at the retail pet product level and then also on the slower innovation ramp that's now implied that parvovirus or is there something else that's contributing to the organization.
For this year and then I have a separate question just on innovation, you mentioned USDA and FDA timelines as it relates to your derm product.
Candidate in Pet health and does that mean, you have both the JAK inhibitor in the IL 31 products around similar timeframe could you have both products launched by 2024 and if you do in fact launched IL 31 product first.
Hi.
Would be extending the timeline for the jacket that silicon it. Thanks.
Thanks, Erinn great questions, Jeff do you want to start on that 22 guide and some of the Companys specific factors and then we'll move to innovation.
Yes, Thanks Erin.
I want to emphasize again that.
As we've said, we're taking a measured and balanced approach many factors Aaron.
That we expected to drive this accelerated growth in the second half changed significantly in the last three months FX as we mentioned most of these of course being macro Theres a high dependency on China as we know for growth and a lot has changed as we mentioned in our comments.
CMO is unable to supply and then just the overall economic slowdown we see.
As you look at specifically to your question on price, we had anticipated a greater than historical level of 2% price. We did expect that to be back end loaded.
Price increases in the first half we've taken additional price increases here mid year for the second half and do expect a step up but two drivers and that caused the price to be lower one was on the farm animal side than the generic markets, especially bovine respiratory disease that was greater than anticipated with.
New market entries in that in that market. The second was yes, and U S pet pair on.
On the retail side under Bob's leadership, and a lot of great things that are happening on our pet retail business.
We made a decision to channel some of the price increased dollars as I mentioned to trade dollars.
To drive demand, we will assess that as we go into this third quarter.
This lowered price, but it actually increased gross to net and drove positive EBITDA.
If we step back and look at price, we continue to see price as a lever we continue to see price stepping up. This half. This will also be a contributor to growth as we lap into 2023 lapping against these price increases and continuing we see elasticity to take more price Pat and even even in protein on our differentiated products.
I'm going to talk about innovation, just what's driving the slower ramp in and then we'll get into sort of the timeline piece of your question yes.
Yes Erin.
First of all I would say.
And all my time in animal health that not seen as I mentioned in my comments as much progress what Alan has done and really a callout to the R&D team and probabilities are up speed is up new spaces are up as we look at now feline diabetes methane rich.
A reduction last quarter derm late last year with kindred, So just as I step back.
<unk> is building I believe a world class innovation engine and animal health under Alan's leadership, and I look forward or coming in November to talk more about it on the ramp yes, we've taken the ramp down a little bit.
I would point to some of the <unk> and that BRD market that I mentioned.
I would also point to experience and I wanted to just emphasize I think it's important maybe to just call out.
Spirit briefly that this is not a matter of.
The value of the compelling value proposition of the product, it's really just a shift in the ramp by one quarter without question question. We missed this ramp timing why it's really the complexity to try the product then transitioned to full feeding coordinate with the Packers, but we do again.
See this trajectory cattle doubled in Q2 versus Q1 more cattle started on in July . We believe we are still very committed to the 6% to $700 million and we believe the leading driver of that will be xperia as a blockbuster and again xperia will be another key growth driver in 2023, and then relative to derm.
Well, we would say is yes, one of the two submissions will make in the next two to four months is derm.
I will say that we haven't articulated which asset is.
Which one I will say, though that the derm portfolio continues to progress nicely.
Both the IL 31, as well as the JAK and the assets behind that came from kindred as well as our own pipeline and Alan will articulate a little bit more of that and we get into that November call.
Thanks, we'll take the next caller.
Your next question will come from the line of Michael <unk> with Bank of America. Please go ahead.
Great. Thanks for taking the question.
I wanted to pick up on something you were just talking about innovation and some of the newer products.
Given.
Given some of the things you just called out and cracks and exterior.
And given what youre seeing for some of the other more recent launches.
Do you think maybe be prudent to reconsider the $600 million to $700 million target about 20, I guess I'm getting at.
Given a slower start.
To that.
Do you see incremental risk to getting those numbers.
Over the next couple of years, and then I'll throw out the follow up question at the same time.
The delay to the long term margin target for gross margins and adjusted EBITDA. There's a lot of inflation macro factors impacting that but you also have some company offsets in terms of pricing power.
They have gone better so.
Yeah.
One is do you have the ability to potentially continue to use those levers to offset those and two is kind of related to that is.
What if inflation doesn't improve what if the supply chain factories don't improve would've China lockdown persists sort of how much risk does that put on over the next 12, So let's say 24 months for a longer performance if these.
If the macro factors that are causing the delay that don't see any improvement. Thanks.
Thanks.
Yeah, Thanks, Mike, Jeff, let's start with the innovation that $700 million and then we'll talk margin targets.
Michael right right question, absolutely, but I would emphasize that again.
The adjustment innovation has driven a lot by potentially the ramp of Xperia, which.
We're extremely confident and even more so this quarter than a quarter ago, and it's really just been a matter of a shift and we see that this will become a blockbuster franchise a lot like the Romans and did in the days that it was launched.
Kind of standard that will be an accelerator or also as you know last year about a half a dozen portfolio enhancing innovations we're doing that again this year that will play as well.
And then I.
I think the most important as you know is the ramping of the pet health blockbusters that are in the pipeline and the probability of those going up and we had a probability based number in that 6% to 700 million that probabilities as I've mentioned have gone up materially and given that our confidence goes up.
The name more than make up for a slower ramp in the innovation. So again, a robust pipeline heavier participation bypass more pet blockbusters and we're also bringing in new spaces. As we've mentioned that also will supplement like feline diabetes.
We brought in that will be a contributor as it is under regulatory review.
Maybe I'll move just quickly to the guidance and give it to Eric.
Our margin targets and give it to Todd maybe for some of the levers Michael but I want to really emphasize a few things in these margin targets first of all we remain committed or adjusting the timing, but we're not changing the commitments and we're not changing our annual progression of margin. We're committed to margin growth in 'twenty, two and 'twenty three 'twenty four going.
Forward our productivity is working there is no question, we face some headwinds the environment has caused us to make an adjustment in the timing not in a change in that commitment and as Todd mentioned in his comments, we were on track to actually exceed them, especially on the gross margin side and I want I want to emphasize that there are some levers that we have in.
Edition.
I would start with the organization with an Eva like ownership mindset, we're finding opportunities every quarter beyond what we thought there's a lot of synergies between Bayer, but maybe Todd you want to you want to highlight a little bit on just some of the the approaches were taken in some of the balance that Michael is challenging us.
Sure Jonathan Thanks for the question Mike.
Youre right, we have taken some price, but we're still running at the 2% historical level, we had expected back at our Investor day, we do foresee increasing price and we've called that out as a driver in the back half of this year as we returned to growth in Q4 with key biggest lever.
Digitally certainly the integration of the bear systems and processes into Lingo as we noted back in February that's $50 million to $60 million of incremental savings on EBITDA.
We'll get that annualized in 'twenty, four and on track for the middle of 2023.
Your question about inflation continue to be hot China document back certainly those are big parts of our business. The team's done a very good job of offsetting significant amount of inflation. That's why we're in the face of having mixed challenges this year, our pet health business down poultry up.
We're expanding gross margin, we think we've got levers yet to go there, especially through the Eva like metric, Jeff mentioned and the ownership mindset, but it is something we have to continue to do what arent getting the lift we get without that.
And then FX component certainly $55 million of EBITDA, We've lost in 2022 versus 2021 based off the current expectations for foreign exchange rates.
Great. Thanks that will move to the next question.
Next question will come from the line of Chris Schott with JP Morgan. Please go ahead.
Alright, great. Thanks, so much for the questions. My first one was just I'm still.
Trying to get my hands around kind of bridging from the <unk> results through subsequent to today.
The guidance that seems like the headwinds youre, referring to were were in place in <unk>, obviously, continuing our stryker into <unk>, but we are seeing a pretty big step down in sales.
We stepped out of margin I, just wanted to start fully understand that issue.
And then my second question was just on <unk> and just talk a little bit about as you think about the U S business, there was going to say.
To get back to maybe a more normalized kind of run rate for that business. Thank you.
Thanks, Chris let's start with Todd for the kind of more full year guidance question and then we'll go to Jeff on threat, though.
Chris Thank you for the question.
On Slide 15, you can see the bridge on the change in our guidance.
Opex clear using rates as of early August and that the $65 million headwind as we think about the impacts in the back half. We had said in May we expected Chinese alopecia recovery in pet health and to get back all the law fills in Q2 and the back half of the year.
It isn't happening the way the recovery is going in China, pork prices continuing to ramp but not at the same pace as our customers break evens are running even higher than we realized and then finally on the poultry side, we've seen a big impact on our poultry business that wasn't visible in may in China.
The supply chain disruption. This is a lot of small items, but are finally catching up to us on end user demand we've been mitigating a number of supply challenges over the last year, but we're finally at a point, where we just don't have a mitigation of those these are 10 $3 million to $4 million of items across.
The globe to serve everything from poultry to pet health to cattle sheep, all small items that are adding up.
Our impact in this in a way that we have to call. It out now as we go into the back half of the year and then just general softness we've got 16 to 22 international kind of affiliate groupings that are growing the top and bottom line, but all of those are starting to slow.
Went into June and July and that's what we're representing with this economic slowdown I don't have a specific item, but it's clear we're seeing a softness across our business, but we wanted to reflect so then again pair of competition that we do see happening in the vet clinic in the second half.
The innovation ramp they expire in cracks crude oil plus those are all back up items versus what we saw in may offset by continued good growth in Aqua and poultry. So those are the drivers and ones we wanted to be clear on today.
And <unk> getting back to normal growth Chris Great. Great question. Thank you again, a lot of belief in Crs till I come back to some of the fundamentals and I can share a little bit on a quarter Sorretto serves an important market an eight month coverage affordable it's convenient it doesn't require that visit there is a large market out.
There as we study the data we did this quarter.
Customers consumer research and we saw a 95% repurchase intent. So a lot of loyalty just what we found in the diligence a lot of return users, but also low awareness overall awareness. So our digital capabilities to grow awareness is important so a resilient bank brand and its differentiated some discrete items.
I would point out Chris that maybe as we look at dispensing a little stronger than maybe the decline in sales we saw a softer season remember retail it takes the warm weather to get people activated to go buy their collar. So in April that cooler weather did have an impact we have a very big business in central East Europe , that's been impacted some by the way.
War.
Again, a strong business in centrally share for <unk> and then we saw some lower retail inventories where the retailers took their inventories down when you taken normalize that yes. There was some increased competition, but I think those discrete items balance that the brand grew 2% year to date and again as we look going forward, Chris It's one.
More more geography without question International is growing very nicely for the resto two its with digital growing more awareness to that segment that doesn't see the veterinarian and then lifecycle management, although those things will be critical as we look at growing this brand, which is our intent that this brand will continue to.
And more than 50% outside the U S. We see a lot of runway for growth with terrestrial great.
Thanks, we'll take the next question.
Your next question will come from the line of Jon Block with Stifel. Please go ahead.
Great guys. Thanks.
Do you have I think I heard you right you talked about gross margin and EBITDA expansion continuing into 2023, and I'm guessing that has to be.
Predicated on some top line numbers, so just any thoughts or commitments for revenue growth in 2023.
Some of the key products that looks like.
It might not be on the table until 2024, and then just longer term when you get some of those key products across the globe and let's focus on the Triple just talk to us about the impact that you think it may or may not have on advantage answer resto, the way that youre going to attack the market. So call. It is more incremental in nature rather than cannibalistic.
Alright. Thanks.
Yes margin expansion and then thinking about the new innovation.
John I. Thank you for the question look when we look at our IPP strategy productivity as work at margin expansion pipelines progression on the innovation side, our portfolio when we step back and look at the algorithm of new products, followed by focused brands and even doing better on defend brands as a whole we still believe that strategy.
As a whole it's going to play out nicely over now to 2025, but growth is a focus so let me emphasize we do expect our business returning to growth in Q4 that includes our pet health business.
Again with the backdrop of the assumptions that we have today, we will assess 2023, but remember even even looking at the importance of things that we see.
On our on our focus brands, our innovation, we see China coming back I mean, what's happening in the second half of 'twenty two we see playing positively in 'twenty three the Cmo's that Todd mentioned, we're adding suppliers, we don't see that being a long problem the price lapping the increasing of innovation led by experienced.
<unk>.
And then the adding of products like Parvo, though we expect their approval late this year early next and the approval. So and then when I step back John and see Hey farm animal, we and a lot of markets are taking share poultry Aqua, we have a leadership position Pat therapy. The non <unk> business is getting to be a higher percentage of <unk>.
Overall in international a statistic I would share 16 of our 22 clusters of countries are growing both topline and bottomline here, even in the second quarter. So I think of durable international business. So growth is our focus we do have durable diverse geography and portfolio.
No question. The second quarter was challenged and then as you look at moving now to the pipeline and pair off what I would emphasize is first of all we are looking at payer of Holistically.
Looking at both first Omnichannel in and outside the Vet clinic and then we're looking at the differences between the international and the U S businesses.
Without question first class is always at a.
Charge, but best in class is equally as important and so when we start to see hey, we've got differentiated offerings with its new pair asset that we believe as we look at hey, how can we capture share. It is the leverage of our channel to leverage of new puppy starts the leverage of being able to complement what we have the leg.
<unk> brands like <unk> will continue to erode, but that's what we expected and our algorithm, but I think when you step back and say the breadth of our portfolio the breadth of the channel and now, bringing new innovation and we see it being net net nicely accretive between now and 2025.
Thanks, we'll take the next question.
Your next question will come from the line of <unk> with Evercore ISI. Please go ahead.
Hi, guys. This is Mike <unk> in for Omar. Thanks, So much for taking my question just two from me.
Number one on guidance how much conservatism would you say is baked into the second half guidance I'm, saying this because on the <unk> call.
By the second half guidance suggested a strong second half rebound, obviously things have changed just wondering if.
Going forward there is a.
Strong element of conservatism baked in the back half of the year.
And the second question is just more on on livestock.
In Q1, you said that pricing.
Has has held up well for producers and that they wanted to keep buying those products to get the most out of feed I'm wondering if that's still the case and if you could provide any color along those lines. Thank you.
Great, let's start with the Todd just on the guidance and then we'll move to Jeff on livestock.
Mike Thanks for the question.
Feel good about the guidance, we're providing today, we don't feel good about the change relative to may but as we look forward and had conversations with all of our key leaders across the company. We're trying to reflect the best view of the current reality, we factored in this kind of a global slowdown and are very <unk>.
Just on continuing to drive positive growth in EBITDA as well as returning to growth on the top line in Q4 for all the reasons, we've already mentioned.
Jeff on livestock, yes, again, a good quarter for our farm animal business overall international in both U S growing nicely I think that comes from some of the diversity and some of the fundamentals.
You mentioned Mike.
The demand for protein remains.
There are some price pressures that we're seeing that are starting to get where prices with some of the economic slowdown is starting to slow slightly I would point to a couple I think poultry is very positive. The demand is very strong globally, because it's a more affordable protein our leadership position in poultry.
Turning to turning higher cost screens into more protein there will be strong same with aqua.
On the spine market, it's everything that Todd just mentioned, it's really for us Swines, all driven by China, and that's more of a balancing of demand and supply in economics prices coming back we're seeing prices coming back in July , but again not to our expectations, but hope for a recovery and then beef I think the dynamic.
I'd just highlight you hear about the droughts and everything that's happening what I see here is more cattle coming out of the farmer feeder calves going into the feed yards. So we will see in the second half of the year Mike.
A higher number of cattle on feed because of the drought and the movement of getting them back into the yards probably for more days because they'll come in at lighter weights.
But our population of the herd, especially in the U S. Beef market is down it will probably take a couple of years. So you'll start to see a little bit of a slowdown I think in herd rebuild in 'twenty three 'twenty four but net net.
Farm animal business pretty resilient here a lot of it is because of the conversion of higher cost feed and protein from our products in animal health.
Great. Thanks, we'll take the next question please.
Our next question will come from the line of Nathan Rich with Goldman Sachs. Please go ahead.
Hi, good morning, Thanks for taking the questions.
On parasiticide, So I guess first Jeff you talked about.
The data on the broadest spectrum parasiticide crossing the heartworm threshold.
Products on the market that's on the market today, I think has 100% efficacy against the development of Heartworm I guess do you see your product is competitive to that.
And then secondly, I wanted to ask you about the shift to more trade funds instead of marketing dollars I think you called that out as a net positive to EBITDA.
Maybe talk about the rationale for making that shift in the commercial strategy and how it impacts your view of growth for that category going forward.
Yes, great Great question, Nate So just real real quick to start on our on our payer assets again, we look through a lens of things that can be differentiated but also the critical thresholds to get the product to market. So as we looked at our <unk> plus as an example, not having that 100% heartworm was.
The Restrictor in has been a restrictor for innovations across many companies. So.
Significant news today that we believe we've we've passed the threshold necessary to bring a broad spectrum next generation product to market beyond that so matching absolutely then beyond that we're looking at and won't articulate great detail now, but we believe that what we have bringing to market at the store.
Agents in is.
Differentiated from what is on the market today, even considering the best in class again more work to be done and.
The label finalized with the FDA, but at this stage, we do see that and Alan will share a little bit more of those details in November as well and then on.
On the retail side again, we believe we've got a great portfolio. The retail market has its ebbs and flows but we've got a leadership position here, we've got leadership brands with a terrestrial advantage, we're innovating against those brands like with advantage XD and and I wanted to just highlight I mean, Bobby Modi coming in with his team.
With some of the Bayer expertise, we have we believe we are well suited to continue to grow and there is a lot of positive trends for retail and the ease of meeting pet owners, where they want to shop, and maybe even a more affordable way in these inflationary times, we made a decision to go ahead and to work closely with our retailers and put more.
Trade dollars in two to increase awareness and increase in our shelf space and share of voice in the retailers will see how that plays out as we saw a slower start in April with the cooler weather. This was one of the moves we made in late in the quarter.
More to come on that but again, our confidence in our in our team and our capability and our portfolio and our innovation and the retail space and.
To see this omnichannel is critical.
Thanks, we'll take the next question.
Our final question will come from the line of Kristine <unk> with William Blair. Please go ahead.
Okay. Good.
Good morning, and thanks for taking the question.
Can you give me some more details on your feline diabetes drug what do you anticipate the market opportunity to be here and also same question for <unk> and then in general how are you marketing these feline product given that sort.
Sort of as we all know cats aren't met our clients at a much lower rate and then just for my second question.
It's really about what your expectations and goals.
Pipeline parvovirus product you have thanks.
Yes, let me try that.
Titles together first of all I think fee line. There is no question.
Under Medicalized.
Not coming to the vet as much as maybe they should we see a real opportunity with codelco cat last year advantage XD coming.
We've got.
<unk> that we've launched here and then we've got this new product that we're bringing in so we continue to see expanding feline diabetes. We're also in a real credit to our team and the digital team any landfill that actually in one month I don't know if <unk> seen this fast of an adoption and any other product 5000 clinics in one month.
Grabbing a hold absorb them because of not only the product, but I believe also in digital strategy Thats working and that will be a capability that we will use for.
For fee line as well as even new products that we're getting ready to launch this feline diabetes product again some of the challenges that you see is.
Being able to get to needle free novel first in class new mechanism of action.
A daily medication, that's really easy to give really opens up an opportunity to show that hey, diabetes can be easily treated.
And this market, we're going to continue the size of this market necessity market, but again a product that is a new mode of action and under regulatory review and expecting that we'll be launching that product as we go into 2023 is another contributor to growth.
And then on Parvo, Yes, Parvo continues to track nicely will be a market as we look at about in the U S.
Somewhere in that 400 to 500000 dogs, a year puppies a year that we're going to be able to be vital to every vet clinic on something thats untreatable today.
We are working through all the final milestones and hope to bring that product into an approval by late this year early next again, another contributor to growth and innovation as we go into 2023 so.
Maybe one last.
The last question, Jeff I'll turn it over to you to close I just thank you everyone for joining this morning in closing I just want to reemphasize.
Some of the key points that are most important <unk> delivered a strong second quarter, our credit to the <unk> team continuing to focus on expanding margins growing EBITDA generating cash and de levering efforts. Despite the sales pressure and a challenging environment here in Q2, we're confident and long.
Term growth and the durability of our business.
And particularly pleased with the significant pipeline progress so far this year and in the next two to four months as I emphasized we will begin the submissions that will really open up the next era of innovation and growth and opportunity for <unk> and this will ultimately lead to increasing value for our customers and our team and our stakeholders.
And then I again want to thank you for your interest in <unk>, we look forward to continuing to engage with you as we go through the rest of this quarter.
Ladies and gentlemen that will conclude today's call. Thank you all for joining you may now disconnect.
Yeah.